EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effect of Roxadustat on bone metabolism markers in patients with renal anemia

Jianglin Yu, Zhijie Lei, Yaxin Chen, Rui Yao, Xiaoyang Qi, Xiang Li, Yixin Chen, Wei Zhu, Xusheng Qiu

Endocrine · 29.12.2025 · 91 (1)

DOI: 10.1007/s12020-025-04475-6 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Endocrine, online erschienen am 29.12.2025. Verfasst von Jianglin Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, Jiangsu Province, China. Hauptthemen laut MEDLINE: Anemia, Bone and Bones, Glycine, Isoquinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health, Jiangsu, China, Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Roxadustat, a prolyl hydroxylase domain inhibitor that stabilizes hypoxia-inducible factor (HIF) expression, is a recently developed drug for the treatment of renal anemia. Studies have shown that HIF activation not only stimulates the production of endogenous erythropoietin but also modulates bone metabolism. Patients with chronic kidney disease (CKD) often present with abnormalities in bone metabolism in addition to concomitant anemia. However, the effect of Roxadustat on bone metabolism markers in patients with renal anemia have rarely been reported. OBJECTIVE: (1) To investigate the effect of Roxadustat on bone metabolism markers in patients with renal anemia; (2) To investigate the effect of Roxadustat on inflammatory and lipid metabolism markers in patients with renal anemia. METHODS: This retrospective observational study enrolled a total of 52 patients with anemia secondary to CKD, who were categorized into a roxadustat group and a control group based on whether they received roxadustat treatment. The following markers, including hemoglobin (Hb), β-C-terminal telopeptide of type I collagen (β-CTX), total type I procollagen intact N-terminal propeptide (tP1NP), parathyroid hormone (PTH), osteocalcin (OC), 25-hydroxyvitamin D (25-OHD), alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P), C-reactive protein (CRP), Procalcitonin (PCT), total cholesterol (TC), low-density lipoprotein (LDL), were measured before and after treatment. The changes of bone metabolism, inflammatory and lipid metabolism markers were compared before and after treatment. RESULTS: After a period of Roxadustat treatment, β-CTX and PTH levels were significantly lower compared to pre-treatment, while tP1NP, 25-OHD, and ALP levels increased compared to pre-treatment (P < 0.05). Inflammatory markers (PCT) and lipid metabolism markers (TC, LDL) were significantly reduced (P < 0.05). No statistically significant differences were observed in the control group. CONCLUSION: In this study, Roxadustat treatment for renal anemia was associated with simultaneous improvements in markers of bone metabolism, inflammation, and lipid metabolism in CKD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaBone and BonesGlycineIsoquinolinesProlyl-Hydroxylase InhibitorsRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedBiomarkersLipid MetabolismParathyroid HormoneRetrospective Studies

Stichwörter der Autor:innen

Bone metabolism markersInflammatory markersLipid metabolism markersRenal anemiaRoxadustat

Substanzen

BiomarkersGlycineIsoquinolinesParathyroid HormoneProlyl-Hydroxylase Inhibitorsroxadustat

Autor:innen und Institutionen

  • Department of Orthopedics, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, Jiangsu Province, China.
  • Department of Nephrology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China.
  • Department of Orthopedics, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210008, Jiangsu Province, China. zhuwell@163.com.
  • Department of Orthopedics, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, 210008, Jiangsu Province, China. qiu_xusheng@163.com.
  • Department of Nephrology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu Province, China. qiu_xusheng@163.com.

Förderung

  • Key Project supported by Medical Science and Technology Development Foundation, Nanjing Department of Health, Jiangsu, China
  • Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University

Zitieren

APA

Yu, J., Lei, Z., Chen, Y., Yao, R., Qi, X., Li, X., Chen, Y., Zhu, W., & Qiu, X. (2025). Effect of Roxadustat on bone metabolism markers in patients with renal anemia. Endocrine, 91(1). https://doi.org/10.1007/s12020-025-04475-6

Vancouver

Yu J, Lei Z, Chen Y, Yao R, Qi X, Li X, et al. Effect of Roxadustat on bone metabolism markers in patients with renal anemia. Endocrine. 2025;91(1). doi:10.1007/s12020-025-04475-6

BibTeX
@article{Yu2025,
  author = {Yu, Jianglin and Lei, Zhijie and Chen, Yaxin and Yao, Rui and Qi, Xiaoyang and Li, Xiang and Chen, Yixin and Zhu, Wei and Qiu, Xusheng},
  title = {Effect of Roxadustat on bone metabolism markers in patients with renal anemia},
  journal = {Endocrine},
  year = {2025},
  volume = {91},
  number = {1},
  doi = {10.1007/s12020-025-04475-6}
}
Kostenlos starten →